TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA issued an Early Alert about Medline’s market exit and field action covering all Medline Brand beds and associated components. Medline’s October 24 update says affected beds may remain in use under specific precautions until repair or replacement, while the FDA reviews the issue.
The U.S. Food and Drug Administration has issued an Early Alert for a potentially high-risk issue involving all Medline Brand beds and associated products, after Medline announced a market exit and customer field action. The FDA says potential hazards include electrical components overheating and risks of entrapment or asphyxiation; Medline’s October 24 update allows affected beds to remain in use under specified precautions until repaired or replaced.
The action covers homecare, bariatric and long-term care beds, as well as bed rails, mattresses, pendants, accessories, replacement parts and packages containing beds. Medline’s October 14, 2026, notice told affected customers about product removal, discontinuation and its market exit. In an updated notice dated October 24, Medline changed its instructions for current users.
Under the revised directions, users should unplug the bed when it is not being adjusted. When repositioning a patient requires an adjustment, plug the bed into an outlet for that task and unplug it afterward. Medline says not to use extension cords and recommends having a second person available to help with bed use and movement whenever possible. The update says covered beds, rails, mattresses and accessories may remain in use under these instructions until the bed is repaired or replaced.
Medline is setting up two routes for affected products: repair for certain eligible beds, or, if a bed or accessories are not eligible for repair, assessment for replacement or a full or partial refund. The company says these options may apply to certain products bought within the past five years. Older products remain subject to the field action and updated safety instructions, but the notice does not state that they qualify for the same financial or replacement options. Users should not attempt repairs or modifications unless Medline specifically directs them through an authorized process.
Fire and Entrapment Risks for Bed Users
The alert concerns equipment used by people who may rely on an adjustable bed for care or mobility, including patients in homes and long-term care settings. A fire, electrical shock or burn could cause severe harm; an entrapment or asphyxiation incident may also result in injury or death. The FDA’s alert identifies these as potential high-risk hazards, rather than stating that every affected bed will experience a failure.
Medline identified possible overheating conditions that include excessive system loading, jammed components, damaged or fluid-exposed pendants, extension-cord use, and unapproved pendants or accessories. The company also reported a separate concern that bed accessories, a user lying on a pendant, or loose or wobbly rails may create entrapment or asphyxiation risks. The FDA says Medline had reported two deaths and 16 serious injuries as of October 20, 2026, associated with the issues. The alert does not provide further case details or break down the reports by hazard.
Popular right now
Shark PowerPro Reveal Plus Cordless Vacuum Cleaner, Charcoal, IZ376H
Breville Bambino Espresso Machine, Brushed Stainless Steel (BES450BSS)
Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation
As an affiliate, we earn on qualifying purchases.
What Medline’s Updated Notice Changes
The FDA’s Center for Devices and Radiological Health describes its Early Alert as a way to notify the public about a potentially high-risk device issue while the agency reviews information. The agency says it will update its alert page as significant new information becomes available. This is a developing regulatory notice; the source material does not say the FDA has completed its review or issued a final determination.
The main change in Medline’s October 24 notice is that it replaces a blanket implication of removal with a conditional path for continued use: covered products may remain in use under the new instructions until repair or replacement. The field action still applies to the products, including those bought more than five years ago. Eligibility for repair, replacement or a refund depends on Medline’s assessment and the product’s circumstances; the notice does not promise the same remedy to every customer.
“Do not use extension cords to power the bed.”
— Medline, in its October 24, 2026, updated customer notification
Scope of Repairs and FDA Review
The FDA says it is reviewing information and will post updates, but the supplied alert does not give a timetable for that review or describe any final agency finding. It also does not identify specific models or serial numbers in the text provided; customers are directed to Medline’s affected-product list and recall information for product-level details.
The notice does not explain which individual beds qualify for repair, how Medline will decide between repair and replacement or refund, or how much eligible customers may receive. Although the FDA reports two deaths and 16 serious injuries as of October 20, 2026, it does not give the circumstances, dates or hazard associated with each report. The information does not establish that every reported event was independently confirmed by the FDA.
Contact Medline and Follow Updates
Customers with potentially affected beds or accessories should check Medline’s affected-product information and contact Medline Recall Customer Service at 1-800-950-0128, option 7, to ask about the repair, replacement or refund process. Users should follow the updated operating instructions, avoid extension cords and unapproved accessories, and not attempt an unauthorized repair.
Medline asks that adverse events be reported to its quality team at QualityAssurance@medline.com or 1-800-950-0128, option 5, and to FDA MedWatch. The FDA says it will update its Early Alert page when significant new information is available. No further agency action or deadline is specified in the source material.
Key Questions
Which Medline products are included in the alert?
The field action covers all Medline Brand beds and associated bed rails, mattresses, pendants, accessories, replacement parts and bed-containing order packages. It includes homecare, bariatric and long-term care beds. Customers should consult Medline’s affected-product information for details on particular products.
Can an affected Medline bed still be used?
Medline’s October 24 update says covered beds and related products may remain in use until a bed is repaired or replaced, provided users follow the revised instructions. Unplug the bed except when it needs to be powered for repositioning, do not use an extension cord, and unplug it after the adjustment. The notice recommends a second person assist whenever possible.
What should customers do about repairs or refunds?
Contact Medline Recall Customer Service at 1-800-950-0128, option 7. Medline says certain beds may qualify for an authorized repair; products found ineligible may be considered for replacement or a full or partial refund. The notice says these options may be available for certain products purchased within the past five years, but does not guarantee eligibility.
What hazards did Medline and the FDA identify?
The alert describes potential overheating that may lead to smoke, sparks, melting, burning or fire, with possible risks including burns and electrical shock. It also identifies potential entrapment or asphyxiation risks involving bed accessories, a person lying on a pendant, or loose or wobbly rails.
How many deaths and injuries were reported?
The FDA says that, as of October 20, 2026, Medline had reported two deaths and 16 serious injuries associated with the issues. The alert does not provide case details or specify how many reports involved fire hazards versus entrapment concerns.
Source: fda.gov
